There is no published consensus benchmark for this lightly covered name, so the clean read is against its own prior-year result—and the quarter weakened beneath the sales headline. Revenue rose 4.6%, but net income fell 9.6%; EPS fell a smaller 4.2% only because the weighted share count was lower. That is a negative underlying earnings comparison, not a clear earnings beat. (Condensed Consolidated Statements of Income)
| Metric | Q2 2026 | Q2 2025 | Change / implication |
|---|---|---|---|
| Total revenue | $1.275B | $1.219B | +4.6% (Condensed Consolidated Statements of Income) |
| Comparable-store sales | +2.3% | +1.8% | Faster reported growth, but fuel matters (Two-Year Stacked Comparable Store Sales) |
| Comparable-store sales, excluding fuel | -0.4% | +2.3% | Core same-store sales reversed lower (Two-Year Stacked Comparable Store Sales) |
| Gross profit margin | 25.8% | 25.3% | +0.6 percentage points, calculated from reported sales and gross profit (Condensed Consolidated Statements of Income) |
| Operating income | $29.1M | $30.2M | -3.7% despite higher revenue (Condensed Consolidated Statements of Income) |
| Net income / EPS | $22.9M / $0.92 | $25.3M / $0.96 | -9.6% / -4.2% (Condensed Consolidated Statements of Income) |
The most important sales detail is softer than the 2.3% comparable-sales headline. Same-store sales excluding fuel declined 0.4%, versus a 2.3% gain a year earlier. In other words, the reported comp increase was supported by fuel rather than broad underlying store growth; the 4.1% two-year stacked comp also masks a deceleration from last year's fuel-free growth. (Two-Year Stacked Comparable Store Sales)
Higher spending absorbed the gross-margin improvement. Gross profit increased 7.1%, faster than revenue, but operating, general and administrative expense rose 8.3%, pushing operating income down 3.7%. Promotions and targeted loyalty investment may support value positioning, but this filing shows those efforts coinciding with weaker quarterly operating leverage. (Condensed Consolidated Statements of Income; Second Quarter 2026 Results)
Pharmacy regulation was a real sales headwind, but it does not fully explain the profit decline. Medicare maximum-fair-price provisions reduced pharmacy revenue growth by about $10.7M in the quarter. Yet the filing also shows lower investment income and higher other expense, alongside the operating-income decline; the earnings pressure was therefore broader than that pharmacy-revenue effect alone. (Second Quarter 2026 Results; Condensed Consolidated Statements of Income)
The first half remains ahead of last year, which tempers—but does not erase—the weaker quarter. Year-to-date net income rose 13.1% to $50.7M and EPS rose to $2.05, largely reflecting a much stronger first quarter. The new information is that second-quarter profitability and fuel-free comparable sales moved the other way, making the first-half gain less indicative of current run-rate momentum. (Year-To-Date 2026 Results; Condensed Consolidated Statements of Income)
Read the original 8-K on SEC EDGAR ↗